These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 26508502

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M.
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [Abstract] [Full Text] [Related]

  • 6. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N.
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [Abstract] [Full Text] [Related]

  • 7. Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
    Kikuchi S, Nobeyama Y, Saeki H, Asahina A.
    J Dermatol; 2020 Mar; 47(3):277-282. PubMed ID: 31912576
    [Abstract] [Full Text] [Related]

  • 8. Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy.
    Kawashima K, Ishihara S, Kinoshita Y.
    Dig Liver Dis; 2016 Jun; 48(6):688-9. PubMed ID: 27012448
    [No Abstract] [Full Text] [Related]

  • 9. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
    Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M.
    Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
    [Abstract] [Full Text] [Related]

  • 10. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance.
    Ashida K, Honda Y, Sanada K, Takemura Y, Sakamoto S.
    Expert Opin Drug Saf; 2019 Dec; 18(12):1255-1261. PubMed ID: 31646920
    [Abstract] [Full Text] [Related]

  • 11. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.
    Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M.
    World J Gastroenterol; 2017 Jan 28; 23(4):668-675. PubMed ID: 28216974
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
    Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S.
    Adv Ther; 2016 Sep 28; 33(9):1519-35. PubMed ID: 27432383
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S, Nishikawa J, Sakaida I.
    Intern Med; 2020 Jan 15; 59(2):153-161. PubMed ID: 31243237
    [Abstract] [Full Text] [Related]

  • 14. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
    Kim SY, Lee SW, Jung SW, Koo JS, Yim HJ, Park JJ, Chun HJ, Lee HS, Choi JH, Kim CD, Ryu HS.
    Helicobacter; 2008 Aug 15; 13(4):282-7. PubMed ID: 18665938
    [Abstract] [Full Text] [Related]

  • 15. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC.
    Helicobacter; 2024 Aug 15; 29(3):e13094. PubMed ID: 38790090
    [Abstract] [Full Text] [Related]

  • 16. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance.
    Graham DY, Lu H, Shiotani A.
    J Gastroenterol Hepatol; 2021 May 15; 36(5):1159-1163. PubMed ID: 32918832
    [Abstract] [Full Text] [Related]

  • 17. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y, Shimoyama T, Mizuki I.
    Scand J Gastroenterol; 2017 Feb 15; 52(2):238-241. PubMed ID: 27806639
    [Abstract] [Full Text] [Related]

  • 18. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K.
    J Dig Dis; 2016 Oct 15; 17(10):670-675. PubMed ID: 27534444
    [Abstract] [Full Text] [Related]

  • 19. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H.
    Helicobacter; 2018 Aug 15; 23(4):e12495. PubMed ID: 29873436
    [Abstract] [Full Text] [Related]

  • 20. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW.
    Gastroenterology; 2022 Sep 15; 163(3):608-619. PubMed ID: 35679950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.